Is BPC-157 Legal in Washington State? How Women Can Access It Safely

What BPC-157 Actually Is (and What It Is Not)

BPC-157 stands for Body Protection Compound-157. It is a synthetic pentadecapeptide, a chain of 15 amino acids, derived from a sequence found in human gastric juice. Researchers first identified its tissue-protective properties in animal models of gut injury in the 1990s. It is not a hormone, not a controlled substance under the DEA Controlled Substances Act, and not an approved drug anywhere in the world.

That last point matters. Because BPC-157 has never cleared an FDA new drug application, it cannot be legally marketed or sold as a drug in the United States. The only pathways that allow a licensed pharmacy to prepare and dispense it to a patient involve federal compounding law, specifically Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

What the Rodent Data Actually Shows

The animal literature is larger than most peptide discussions acknowledge. Studies in rats and mice have shown BPC-157 to accelerate healing of tendons, ligaments, and gut mucosa, reduce inflammation in colitis models, and appear to modulate dopaminergic and serotonergic pathways in the central nervous system. One frequently cited paper published in the Journal of Physiology found that BPC-157 accelerated Achilles tendon healing in a rat model compared to controls, though the authors noted the mechanism remained incompletely characterized.

Animal data does not translate automatically to human women. Sex-specific rodent data on BPC-157 is thin. Most studies use male rats. This is a real evidence gap, and you deserve to know it before spending money on a prescription.

What the Human Data Shows (Spoiler: Very Little)

As of early 2025, no completed, peer-reviewed Phase 2 or Phase 3 randomized controlled trial in humans has been published for BPC-157 for any indication. A small open-label pilot in patients with inflammatory bowel disease conducted in Croatia in the early 2000s suggested tolerability, but it was never followed by a larger trial. The National Institutes of Health ClinicalTrials.gov registry lists no currently active registered Phase 3 trial for this compound.

The honest answer is that nobody knows the optimal human dose, the therapeutic window, the long-term safety profile, or the sex-specific pharmacokinetics in women across reproductive stages.

The Federal Legal Framework: Where BPC-157 Actually Stands

Understanding your legal access options in Washington requires understanding federal law first, because Washington state law adds almost nothing on top of it.

FDA's Bulk Drug Substances List

The FDA regulates which active pharmaceutical ingredients (APIs) compounding pharmacies may use. The agency maintains two nomination categories:

• Category 1: Substances nominated and under active review, considered eligible for use in compounding while evaluation proceeds.
• Category 2: Substances the FDA has identified as presenting safety concerns or lacking sufficient evidence to support compounding use; pharmacies are expected to exercise caution.

BPC-157 was placed on the FDA's Category 2 bulk drug substances list in 2023. The FDA has stated that it lacks adequate information to determine whether BPC-157 is safe and effective for use in compounding. This does not make it federally illegal to prescribe or possess, but it means a 503A compounding pharmacy that prepares it may be operating outside FDA guidance, which carries regulatory risk for that pharmacy.

503A vs. 503B Compounding

A 503A pharmacy compounds drugs for individual patients based on a valid prescription from a licensed practitioner. It is not required to register with the FDA but must comply with USP standards and state board rules. Most peptide prescriptions for individual patients flow through 503A pharmacies.

A 503B outsourcing facility produces larger batches without patient-specific prescriptions and is FDA-registered. BPC-157 is not on the FDA's list of bulk drug substances for 503B outsourcing facilities, meaning a 503B facility legally cannot compound it for distribution.

The practical result: the only legal path for a Washington woman to obtain compounded BPC-157 is through a 503A pharmacy acting on a valid individual prescription, and even then the pharmacy is compounding a Category 2 substance against FDA guidance.

Washington State Law: What It Adds (and What It Does Not)

Washington State has its own pharmacy regulatory body, the Washington State Pharmacy Quality Assurance Commission (PQAC), which operates under the Washington State Department of Health. The PQAC licenses pharmacies and pharmacists and sets compounding standards.

Washington state law does not have a specific statute that names BPC-157 and bans it. There is no state-level equivalent of a controlled substance scheduling for this peptide. What Washington does have is a requirement that compounding pharmacies comply with federal USP standards and that prescriptions come from practitioners with a valid Washington license and a legitimate patient-practitioner relationship.

What "Legitimate Patient-Practitioner Relationship" Means for You

In Washington, a valid prescription for a compounded substance requires that your prescribing clinician has:

1. Conducted a documented clinical evaluation (telehealth qualifies under Washington's telehealth parity law).
2. Established a diagnosis or clinical rationale for the prescription.
3. Maintained a patient record.

Buying BPC-157 from an online "research chemical" vendor as a raw powder is a different legal situation entirely. Those vendors typically label products "not for human use" to avoid FDA enforcement. Purchasing, possessing, or self-administering such a product is not protected by any prescription framework. While personal possession of a non-controlled substance is not itself a criminal offense under Washington state law in most circumstances, the product itself has no verified purity, sterility, or dosing accuracy.

How to Access BPC-157 Legally in Washington: Step by Step

This is a practical framework specific to Washington State women seeking legitimate clinical access to BPC-157:

Step 1. Find a Washington-licensed provider willing to evaluate you. This may be a naturopathic physician (ND), an MD or DO specializing in functional or regenerative medicine, or a women's-health NP. Telehealth consultations with Washington-licensed providers count. The provider must have a real clinical rationale for your prescription.

Step 2. Confirm the pharmacy is a licensed 503A compounder in Washington or ships legally to Washington. Ask the pharmacy directly whether they compound BPC-157, whether their facility is PCAB-accredited or USP 797-compliant, and whether they will accept your prescription. Not all compounding pharmacies will prepare Category 2 substances.

Step 3. Understand the formulation. BPC-157 is compounded most often as a lyophilized powder for reconstitution and subcutaneous injection, or as an oral capsule. The injectable route is what the animal literature primarily studied. Oral bioavailability in humans is unknown but theorized to be lower. Your provider should discuss route of administration and explain the dose rationale, given that no established human dosing exists.

Step 4. Document your decision-making. Ask your provider to note in your chart the clinical rationale, the off-label and investigational nature of the peptide, and your informed consent. This protects you and creates a record if questions arise.

Step 5. Do not purchase from research chemical vendors. This bears repeating. Third-party testing of peptides sold as "research chemicals" has found significant purity variation and, in some cases, contamination. A 2021 analysis of peptides purchased online found that fewer than 50% of samples contained the labeled compound at the stated concentration. A licensed compounding pharmacy operating under USP 797 provides sterility and potency testing that a research vendor does not.

BPC-157 and Women's Health: Where the Conversation Is Happening

Women are seeking BPC-157 for a range of reasons, most of them driven by online communities and practitioner interest in areas where conventional medicine has limited options. Here is an honest look at each area.

Gut Health and Leaky Gut Syndrome

Women report higher rates of irritable bowel syndrome than men, at approximately 2:1 female-to-male prevalence. BPC-157's most studied mechanism in animals is gut mucosal protection, which has generated genuine clinical interest. The animal data on colitis, gastric ulcer healing, and intestinal permeability is consistent and reproduced across multiple labs. Whether this translates to symptomatic IBS or intestinal permeability in women has not been tested in any published human RCT.

PCOS and Metabolic Health

Women with polycystic ovary syndrome carry a higher burden of systemic inflammation and gut dysbiosis compared to women without PCOS, based on emerging research in the PCOS literature. Some practitioners are exploring BPC-157 as an adjunct in this context, theorizing that its anti-inflammatory and gut-protective properties could be relevant. This is entirely speculative at present. No trial has enrolled women with PCOS to study BPC-157.

Perimenopause and Joint Pain

Perimenopause, the transition typically beginning in a woman's mid-40s, brings estrogen fluctuation that contributes to joint pain, tendon laxity, and musculoskeletal discomfort in a significant proportion of women. BPC-157's tendon and ligament healing data in animal models has attracted interest from this group. The Menopause Society's 2023 position statement on menopause and musculoskeletal health does not mention BPC-157, which reflects where the evidence stands: not there yet.

Post-Surgical and Injury Recovery

Women undergoing orthopedic procedures, pelvic floor repairs, or other surgeries sometimes ask about BPC-157 for recovery support. Again, animal data is promising. Human data is absent. A woman considering this post-surgically should raise it with her surgeon before the procedure, not after.

Thyroid and Autoimmune Conditions

Women represent approximately 80% of autoimmune disease cases, and thyroid autoimmunity (Hashimoto's thyroiditis, Graves' disease) is among the most common. Some functional medicine practitioners have begun asking whether BPC-157's anti-inflammatory effects could be relevant in autoimmune thyroid disease. No published data supports this use. It is hypothesis-generating at best.

Pregnancy, Breastfeeding, and Contraception: Required Reading

BPC-157 is not recommended during pregnancy or breastfeeding. Full stop.

There are no human studies of BPC-157 in pregnant women. Animal teratogenicity data is not available in the published literature in a form that would support safety conclusions. Because BPC-157 is a peptide, placental transfer is theorized to be limited by molecular weight and enzymatic degradation, but this has not been studied in humans or in any peer-reviewed animal pregnancy model.

Regarding lactation, no data on BPC-157 transfer into breast milk exists. The LactMed database maintained by the NIH does not have an entry for BPC-157, which reflects the absence of any published lactation data.

If you are pregnant, trying to conceive, or breastfeeding:

• Do not use BPC-157 in any form.
• Inform your provider that you are in any of these stages before any peptide discussion begins.
• If you are in the trying-to-conceive window, discuss timing with your reproductive endocrinologist or OB-GYN before starting and before stopping any compounded peptide.

BPC-157 is not a known teratogen because it has not been studied, not because it has been cleared. The absence of evidence of harm is not evidence of absence of harm, and the precautionary principle applies to all compounds without pregnancy safety data when you are pregnant or planning to be.

Women who are prescribed BPC-157 and who are sexually active with pregnancy possible should use reliable contraception during the treatment period, not because BPC-157 is a confirmed teratogen, but because no safety margin has been established.

Who This May Be Right For (and Who Should Not Pursue It)

Women Who May Have a Reasonable Conversation With a Provider About BPC-157

• Women with documented inflammatory gut conditions (Crohn's disease, ulcerative colitis) who have not responded adequately to standard care and whose gastroenterologist is willing to engage with the discussion.
• Women with post-surgical tendon or ligament injuries seeking adjunct recovery support, who understand they are in investigational territory.
• Women in perimenopause with musculoskeletal complaints who have already optimized hormone therapy and other evidence-based interventions.
• Women with PCOS who are working with a provider in a functional or integrative context and who understand that peptide use is off-label and investigational.

Women Who Should Not Pursue BPC-157 at This Time

• Pregnant women, women trying to conceive, and breastfeeding women. No exceptions based on current data.
• Women with a personal or family history of hormone-sensitive cancers, given the complete absence of oncologic safety data for this peptide.
• Women who are not currently connected with a Washington-licensed provider willing to oversee the prescription and monitor outcomes.
• Women who would be obtaining BPC-157 from any source other than a licensed 503A compounding pharmacy acting on a valid prescription.

The Evidence Gap: What Women Specifically Are Owed

Clinical research has historically enrolled fewer women than men, and peptide research is no exception. The NIH policy requiring sex as a biological variable in preclinical research was introduced in 2016, but the existing BPC-157 animal literature largely predates this policy and uses predominantly male rodents. This means the pharmacokinetics, effective dose range, and side effect profile of BPC-157 in female physiology, including the effects of fluctuating estrogen and progesterone on peptide metabolism, are genuinely unknown.

Estrogen affects gut motility, intestinal permeability, and immune response. If BPC-157 acts on these pathways, its effects may differ between premenopausal and postmenopausal women, and may shift across the menstrual cycle. No researcher has studied this. If a provider cannot acknowledge this gap, that is itself a red flag.

As WomanRx reviewer Maya Okafor, MD, puts it: "The peptide conversation in women's health is moving faster than the data. My job is to tell patients what we know, what we don't know, and what the regulatory situation actually is, so they can make a real decision, not a hopeful one."

Frequently Asked Questions